Objective To compare the safety and efficacy of midazolam given intranasally with diazepam given intravenously in the treatment of children with prolonged febrile seizures. Design Prospective randomised study. Setting Paediatric emergency department in a general hospital. Subjects 47 children aged six months to five years with prolonged febrile seizure (at least 10 minutes) during a 12 month period. Interventions Intranasal midazolam (0.2 mg/kg) and intravenous diazepam (0.3 mg/kg).
Introduction
Convulsions triggered by fever (febrile seizures) are the most common type of seizures in childhood, with a prevalence of 3-4%.
1 Acute onset of febrile seizures requires prompt medical attention, ventilation support, and appropriate oxygenation until they either stop spontaneously or are controlled by drugs.
Diazepam is the most widely used drug for the acute management of all types of seizures in both adults and children. 2 However, it has a short duration of action, should be given intravenously or rectally (since its absorption is slow if given intramuscularly), and tends to accumulate if repeated doses are given, with the possible rare complication of brain stem depression leading to bradypnoea or even respiratory arrest. The introduction of an intravenous line may be difficult, particularly in children with generalised tonicclonic febrile seizures. 3 4 Diazepam may also be given rectally to control seizures, which is as effective as intravenous diazepam. 5 A literature review in 1990 identified only three cases of reversible respiratory depression in 843 patients with seizures. 6 Midazolam, the first water soluble benzodiazepine, is widely accepted as a parenteral anxiolytic and premedicant. 7 Its safety and efficacy as an anticonvulsant drug given intramuscularly have been shown in several studies in animals and humans (adults and children). 3 4 8 9 Midazolam given intranasally as an anaesthetic agent has been shown to be safe and effective in children undergoing various diagnostic studies and minor surgical procedures. [10] [11] [12] [13] Intransal midazolam also suppresses epileptic activity and improves the background of electroencephalograms in children with epilepsy. 14 We recently showed that intranasal midazolam is safe and effective for the management of acute seizures in children. 15 In the present study, we aimed to compare midazolam given intranasally with diazepam given intravenously for the treatment of febrile seizures in children.
Subjects and methods
Our study was performed at the Pediatric Emergency Department of Assaf Harofeh Medical Center in Zerifin, Israel, a general hospital affiliated with a university. Over 12 months, all children between the ages of six months and five years who presented with febrile seizures (tonic, clonic, or tonic-clonic) lasting for at least 10 minutes were eligible for inclusion in our study. Febrile seizures were diagnosed retrospectively on the basis of clinical data (history, physical findings, and cerebrospinal fluid results). We excluded children with established intravenous lines or those who had received anticonvulsants before admission. We chose 10 minutes of ongoing motor seizure as the entry criterion, as most emergency physicians would initiate anticonvulsive treatment after that time. 3 We estimated that upon arrival at the hospital children would have had seizures for at least 10 minutes as that is the least time it would take to reach the hospital from the nearest cities.
After seizures were controlled in the children, their parents were asked to sign a consent form giving permission to enrol them in our study. The hospital's ethics committee approved the study on the understanding that, because midazolam is rapidly taken up by the intranasal route, there would be no significant delay in treating patients randomised to receive this drug, and that if this treatment failed an intravenous line would immediately be introduced. Children with febrile seizures received routine life support on admission to hospital. We randomly assigned 100 episodes of febrile seizure to treatment with either intranasal midazolam 0.2 mg/kg or intravenous diazepam 0.3 mg/kg, the maximum dose being 10 mg. Randomisation was performed in advance with a random number table by a hospital pharmacist not involved in the study, and treatment allocations were sealed in opaque envelopes. Investigators were blind to these allocations.
Midazolam solution (5 mg/ml) was dripped by syringe into both nostrils in equal doses, and an intravenous line was immediately introduced. We recorded the following times: arrival at hospital, treatment with intranasal midazolam, intravenous access, cessation of seizures, and recurrence. Treatment was considered successful if the seizure ceased within five minutes. Seizures that stopped between five and 10 minutes after treatment were defined as successful but delayed control of seizure. Seizures that did not stop within 10 minutes after treatment were defined as treatment failures, and intravenous diazepam 0.3 mg/kg was given. Seizures that were controlled with midazolam or diazepam but recurred within 60 minutes were defined as recurrent seizures.
During seizure activity and for 60 minutes after control, the children were followed by continuous cardiorespiratory and pulse oximetry monitors. Vital signs were recorded every 15 minutes. During seizure activity, high flow oxygen was provided through a mask. All the children were admitted to the paediatric ward for 24 hour observation after cessation of seizures.
The results are presented as means (standard deviations) and 95% confidence intervals for continuous data and proportions for nominal data. We compared the two groups by independent sample t test or Fisher's exact test. We estimated the duration of seizure after arrival at hospital between the two groups from survival curves produced by using the KaplanMeier method and the log rank statistics.
Results
Overall, 53 children were eligible for our study. We excluded nine children owing to spontaneous cessation of seizure: five (one with bacterial meningitis) were randomised to receive intranasal midazolam, and four (one with viral meningitis) were randomised to receive intravenous diazepam (fig1).
Intranasal midazolam was given for 26 episodes of febrile seizures in 21 children and intravenous diazepam for 26 episodes in 23 children. Overall, 40 children had one seizure and four children had three recurrent seizures. On each occasion these children were rerandomised to either treatment group. Two seizures in the diazepam group were controlled with intravenous phenobarbital. Statistically significant differences were found between the time of treatment and control of seizures. Time from arrival at hospital to treatment was faster in the midazolam group. Seizures were controlled faster in the diazepam group, and the time from arrival at hospital to control of seizure was faster in the midazolam group. Survival analysis showed a significant difference between the time to cessation of seizures after arrival at hospital in the two groups (fig 2) . Two children with recurrent seizures, one in each group, failed to respond to midazolam and diazepam. Both were successfully controlled with intravenous phenobarbital.
None of the children had clinical signs of respiratory distress, bradycardia, or other side effects. Electrocardiograms, blood pressure, and the results of pulse oximetry were normal in all children during seizure activity and 60 minutes after cessation of seizures. 
Discussion
Midazolam given intranasally is as safe and effective as diazepam given intravenously in the management of febrile seizures in children. Midazolam, a 1,4-benzodiazepine agent of the group of 1,2-unrelated benzodiazepines, is a water soluble compound. It has been extensively used in anaesthetic practice since 1982, and its pharmacology and pharmacokinetics are well known. 16 The drug is hydrophilic at its prepared pH of 3.5 and is therefore reliably absorbed intramuscularly. At physiological pH, its ring structure closes, it becomes highly lipophilic, readily crosses the bloodbrain barrier, and enters the central nervous system, with rapid clinical effects. 17 18 The elimination half-life of midazolam is usually between 1.5 and 3.5 hours. 16 Several studies have found it effective as an anticonvulsant-it inhibited convulsions in mice to a greater extent than diazepam. 8 9 Midazolam given intramuscularly was effective in controlling convulsions in pigs, but its onset of action was not as fast as when given intravenously. 19 The activity of interictal spike waves in adults with epilepsy was successfully abolished with intramuscular midazolam and intravenous diazepam. 9 The safety and efficacy of midazolam has been shown by several clinical studies in epileptic adults and children, 3 4 9 and continuous infusion of midazolam has successfully controlled status epilepticus in adults and children. [20] [21] [22] Midazolam given intravenously or intramuscularly is not associated with respiratory changes, although there are reported associations with hypertension, bradycardia, and hypoxia in adults and children. These changes were, however, mild and transient. No patient had to be intubated or mechanically ventilated. 22 23 As a result of the popularity of intranasal midazolam as a sedative agent for minor surgical interventions and diagnostic procedures, there is considerable information on its use in young children. The elimination half-life of intranasal midazolam at a dose of 0.2 mg/kg is similar to that when the drug is given intravenously, 24 and no significant complications have been reported when it is given by the intranasal route. Therefore, it seemed pertinent to investigate the use of intranasal midazolam in the management of acute seizures, especially in children, where the introduction of an intravenous line is frequently unsuccessful.
One study found that intranasal midazolam given to epileptic children without clinical seizures (who were continuously monitored by electroencephalography) was absorbed rapidly through the nasal mucosa, and that it could suppress epileptic activity and improve the background for electroencephalography.
14 None of the 19 children included in this study had apnoea or bradycardia.
We recently showed that intranasal midazolam is effective in the management of acute seizures in children. 15 In 19 out of 20 children, control of seizures was achieved within 3.5 (SD 0.8) minutes of starting midazolam. None of the children had clinical signs of respiratory distress or bradycardia.
To our knowledge, no controlled studies have compared the efficacy of intranasal midazolam with intravenous diazepam for the management of febrile seizures. We found that seizures were controlled faster with intravenous diazepam than with intranasal midazolam but that midazolam was as safe and effective as diazepam. The time to cessation of seizure was shorter with intranasal midazolam.
A potential weakness of our definition of efficacy as being control of seizures under five minutes is the possibility of spontaneous cessation of seizures irrespective of treatment within this time. We attempted to minimise this limitation by choosing ongoing seizure for at least 10 minutes as our entry criterion to the study, assuming that the chance for spontaneous cessation of such prolonged seizures is low.
Although upper respiratory tract infection might help absorption by increasing blood flow to the nasal mucous membrane, the presence of nasal secretions could dilute the midazolam solution and interfere with its contact with the absorbing surface. Most of the children in our study had upper respiratory tract infections, but this only affected the absorption of midazolam and subsequent seizure control in three episodes.
Acute seizures have been treated with oral diazepam and lorazepam, sublingual lorazepam, rectal solutions of lorazepam and diazepam, and diazepam suppositories. [25] [26] [27] [28] Giving the drugs orally or sublingually is frequently difficult and hazardous when children are convulsing, and absorption of diazepam and lorazepam tablets and rectal lorazepam solution are relatively slow. 29 Rectal diazepam can be given safely in a prehospital environment by medical and non-medical staff, as a means of providing immediate treatment for prolonged seizures. This may shorten the duration of seizures and simplify the management of these patients in the emergency department. 5 Because our study was designed to investigate an alternative means of treating prolonged febrile seizures in an emergency setting, we chose to compare intranasal midazolam with intravenous rather than rectal diazepam, as the rectal route is not always reliable Time of cessation of seizure after giving drug 3.1 (2.2) (2.9 to 3.3) 2.5 (1.9) (2.4 to 2.6)
Time to cessation of seizure after arrival at hospital 6.1 (3.6) (6.3 to 6.7) 8.0 (4.1) (7.9 to 8.3)
P<0.001 for all groups. owing to variable bioavailability and wide range of serum concentrations. 30 31 Rectal diazepam in the form of a gel was recently introduced as another effective and well tolerated treatment for acute repetitive seizures, which can be administered at home by trained caregivers. 32 In conclusion, intranasal midazolam could be provided not only in medical centres but, with appropriate instruction, by the parents of children with febrile seizures at home. Further studies are, however, needed on a larger series of children with various types of seizures.
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